Clinical features and outcomes of all older adults with cHL in the modern management era (diagnosis January 2000 to December 2019)
| Clinical features . | N = 401 (% or range) . | 5-y PFS (%) . | P value . | 5-y OS (%) . | P value . | 5-y DSS (%) . | P value . |
|---|---|---|---|---|---|---|---|
| Age, y | |||||||
| Median (range) | 70 (60-93) | ||||||
| 60-69 | 182 (45) | 68 | <.001 | 72 | <.001 | 78 | <.001 |
| 70-79 | 147 (37) | 45 | 48 | 59 | |||
| ≥80 | 72 (18) | 17 | 22 | 34 | |||
| Sex | |||||||
| Male | 232 (58) | 48 | .25 | 51 | .11 | 61 | .06 |
| Female | 169 (42) | 53 | 58 | 67 | |||
| Stage | |||||||
| Advanced stage | 278/385 (72) | 47 | .011 | 51 | .012 | 59 | <.001 |
| Limited stage | 107/385 (28) | 65 | 70 | 80 | |||
| Extranodal any | 120 (30) | 39 | 41 | 48 | |||
| B symptoms | 187/386 (48) | 46 | .12 | 49 | .048 | 59 | .049 |
| No B symptoms | 199/386 (52) | 57 | 63 | 71 | |||
| Bulky ≥ 10 cm | 35/368 (10) | 59 | .37 | 68 | .16 | 71 | .50 |
| Nonbulky | 333/368 (90) | 53 | 56 | 66 | |||
| PS | |||||||
| PS ≥ 2 | 169/388 (44) | 31 | <.001 | 34 | <.001 | 42 | <.001 |
| PS 0 or 1 | 219/388 (56) | 67 | 71 | 81 | |||
| cHL subtypes | |||||||
| Nodular sclerosis | 182 (45) | 52 | .010 | 56 | .045 | 67 | <.001 |
| Mixed cellularity | 75 (19) | 55 | 58 | 64 | |||
| Lymphocyte rich | 24 (6) | 91 | 91 | 91 | |||
| Lymphocyte depleted | 8 (2) | 25 | 25 | 25 | |||
| Not otherwise specified | 112 (28) | 37 | 42 | 54 | |||
| EBV | |||||||
| Positive | 84/166 (51) | 49 | .13 | 51 | .029 | 62 | .024 |
| Negative | 82/166 (49) | 59 | 63 | 76 |
| Clinical features . | N = 401 (% or range) . | 5-y PFS (%) . | P value . | 5-y OS (%) . | P value . | 5-y DSS (%) . | P value . |
|---|---|---|---|---|---|---|---|
| Age, y | |||||||
| Median (range) | 70 (60-93) | ||||||
| 60-69 | 182 (45) | 68 | <.001 | 72 | <.001 | 78 | <.001 |
| 70-79 | 147 (37) | 45 | 48 | 59 | |||
| ≥80 | 72 (18) | 17 | 22 | 34 | |||
| Sex | |||||||
| Male | 232 (58) | 48 | .25 | 51 | .11 | 61 | .06 |
| Female | 169 (42) | 53 | 58 | 67 | |||
| Stage | |||||||
| Advanced stage | 278/385 (72) | 47 | .011 | 51 | .012 | 59 | <.001 |
| Limited stage | 107/385 (28) | 65 | 70 | 80 | |||
| Extranodal any | 120 (30) | 39 | 41 | 48 | |||
| B symptoms | 187/386 (48) | 46 | .12 | 49 | .048 | 59 | .049 |
| No B symptoms | 199/386 (52) | 57 | 63 | 71 | |||
| Bulky ≥ 10 cm | 35/368 (10) | 59 | .37 | 68 | .16 | 71 | .50 |
| Nonbulky | 333/368 (90) | 53 | 56 | 66 | |||
| PS | |||||||
| PS ≥ 2 | 169/388 (44) | 31 | <.001 | 34 | <.001 | 42 | <.001 |
| PS 0 or 1 | 219/388 (56) | 67 | 71 | 81 | |||
| cHL subtypes | |||||||
| Nodular sclerosis | 182 (45) | 52 | .010 | 56 | .045 | 67 | <.001 |
| Mixed cellularity | 75 (19) | 55 | 58 | 64 | |||
| Lymphocyte rich | 24 (6) | 91 | 91 | 91 | |||
| Lymphocyte depleted | 8 (2) | 25 | 25 | 25 | |||
| Not otherwise specified | 112 (28) | 37 | 42 | 54 | |||
| EBV | |||||||
| Positive | 84/166 (51) | 49 | .13 | 51 | .029 | 62 | .024 |
| Negative | 82/166 (49) | 59 | 63 | 76 |